Aspergillus DNA and Mycotoxin Detection via PCR-Immuno Assay

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for diagnosing fungal infections caused by Aspergillus terreus and Aspergillus niger are often late and unreliable, due to difficulties in differentiating invasive mold infections and the lack of sensitive and specific diagnostic tools for detecting DNA and mycotoxins in patient tissues and body fluids.

Innovation Solution

Development of methods and compositions for detecting Aspergillus terreus DNA and mycotoxins, and Aspergillus niger DNA and mycotoxins, using PCR-based amplification and antibody-based identification, with specific primers and probes to amplify and identify the fungal species and toxins in patient samples.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional diagnostic methods are used for fungal infections, then the diagnostic process is simple, but the diagnosis is often late and unreliable with low sensitivity and specificity

Engineering Contradiction:
Improvediagnostic reliabilityVSAvoiddetection method complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines PCR-based DNA detection with antibody-based mycotoxin detection into a single comprehensive diagnostic system. This merging of molecular biology techniques (PCR amplification with specific primers and probes) and immunological techniques (antibody identification) creates a unified diagnostic approach that simultaneously detects fungal DNA and mycotoxins, thereby improving diagnostic reliability while managing complexity through integrated methodology

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The patent introduces specific primers and probes as intermediaries in the PCR amplification process. These specially designed nucleic acid sequences act as mediators that selectively bind to and amplify target fungal DNA sequences, enabling specific identification of Aspergillus species. The antibodies also serve as intermediaries that specifically recognize and bind to mycotoxins, facilitating their detection through signal amplification mechanisms

Inventive Principle:
Principle #24Intermediary (Mediator)

2Measurement precision

If PCR-based amplification and antibody-based identification are used, then detection sensitivity and specificity are improved, but the device and procedure complexity increases

Engineering Contradiction:
Improvedetection precisionVSAvoiddetection system complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the detection process into distinct functional modules: DNA extraction from clinical specimens, PCR amplification using specific primers, probe hybridization for species identification, and parallel antibody-based mycotoxin detection. This segmentation allows each component to be optimized independently for precision while maintaining overall system manageability through modular architecture

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent utilizes parameter changes in the PCR process, including specific temperature cycling conditions, primer concentrations, and probe labeling parameters, to optimize detection precision. The use of fluorescently labeled probes and antibodies with specific binding affinities represents parameter optimization that enhances measurement precision while controlling the complexity of the detection system

Inventive Principle:
Principle #35Parameter changes

3Loss of time

If early diagnosis is achieved through sensitive detection methods, then treatment effectiveness is improved, but the complexity of sample analysis increases

Engineering Contradiction:
Improvediagnosis timeVSAvoidsample analysis complexity
Core Design Contradiction:
Loss of timeVSDevice complexity

Solution Approach 1:

The patent employs preliminary action through the design of specific primers and probes that are pre-configured to target conserved regions of Aspergillus DNA. This preliminary preparation of detection reagents with known specificities allows for rapid amplification and identification without requiring complex real-time decision-making during analysis, thereby reducing diagnosis time while managing analytical complexity

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent creates a universal detection system that can identify multiple Aspergillus species (including A. terreus and A. niger) and detect their mycotoxins using a common PCR platform and antibody-based detection methodology. This multi-functional approach allows simultaneous detection of different fungal targets and toxins in a single diagnostic workflow, reducing overall diagnosis time while consolidating analytical complexity into a unified system

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Provides reliable, sensitive, and specific detection of Aspergillus species in patient tissues and body fluids, enabling early diagnosis and effective treatment of fungal infections.

Implementation Method 1

PCR-based amplification and antibody-based identification, with specific primers and probes to amplify and identify the fungal species and toxins in patient samples

Methodology Applied
Scientific EffectPCR amplification:

Implementation Method 2

antibody-based identification, with specific primers and probes to amplify and identify the fungal species and toxins in patient samples

Methodology Applied
Scientific EffectAntigen-antibody binding:

Data Source

PatentUS9150934B2Methods and compositions for detecting <i>Aspergillus terreus, Aspergillus niger</i>, and mycotoxins
Publication Date: 2015.10.06 REALTIME LABORATORIES INC

AI summary

The invention relates to a method of identifying an Aspergillus terreus or an Aspergillus niger fungal species in patient tissue or body fluid and to primers and probes for use in such a method.